hydroxyurea has been researched along with Duncan Disease in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea is an antimetabolite drug used in the treatment of myeloproliferative disorders." | 5.40 | [Hydroxyurea-induced pneumonia]. ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014) |
| "Hydroxyurea is an antimetabolite drug used in the treatment of myeloproliferative disorders." | 1.40 | [Hydroxyurea-induced pneumonia]. ( Claeyssen, V; Decaux, O; Delaval, P; Desrues, B; Girard, A; Jouneau, S; Poullot, E; Ricordel, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamada, T | 1 |
| Kawata, M | 1 |
| Maeda, Y | 1 |
| Yoshino, T | 1 |
| Miyake, T | 1 |
| Morizane, S | 1 |
| Hirai, Y | 1 |
| Iwatsuki, K | 1 |
| Gotlib, J | 1 |
| Girard, A | 1 |
| Ricordel, C | 1 |
| Poullot, E | 1 |
| Claeyssen, V | 1 |
| Decaux, O | 1 |
| Desrues, B | 1 |
| Delaval, P | 1 |
| Jouneau, S | 1 |
| Mayhew, CN | 1 |
| Phillips, JD | 1 |
| Cibull, ML | 1 |
| Elford, HL | 1 |
| Gallicchio, VS | 1 |
| Petti, MC | 1 |
| Tafuri, A | 1 |
| Latagliata, R | 1 |
| Aloe Spiriti, MA | 1 |
| Montefusco, E | 1 |
| Mancini, M | 1 |
| Meloni, G | 1 |
| Petrucci, MT | 1 |
| Spadea, A | 1 |
| Redi, R | 1 |
| Alimena, G | 1 |
| Mandelli, F | 1 |
| Pakakasama, S | 1 |
| Eames, GM | 1 |
| Morriss, MC | 1 |
| Huls, MH | 1 |
| Rooney, CM | 1 |
| Heslop, HE | 1 |
| Krance, RA | 1 |
| Henry, L | 1 |
| Carillo, S | 1 |
| Jourdan, E | 1 |
| Arnaud, A | 1 |
| Brun, S | 1 |
| Lavabre-Bertrand, T | 1 |
1 review available for hydroxyurea and Duncan Disease
| Article | Year |
|---|---|
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Bone Marrow Examination; Clone Cells; Disease Manage | 2014 |
6 other studies available for hydroxyurea and Duncan Disease
| Article | Year |
|---|---|
Epstein-Barr virus-positive mucocutaneous ulcer in a patient with polycythemia vera treated with oral hydroxyurea.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; E | 2018 |
[Hydroxyurea-induced pneumonia].
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Lymphoproliferative Disorders; Pneumonia; | 2014 |
Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea.
Topics: Animals; Antiviral Agents; Benzamidines; Blood Cell Count; Body Weight; Bone Marrow; Hydroxamic Acid | 2002 |
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat | 2003 |
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.
Topics: Adult; Brain; Child, Preschool; Epstein-Barr Virus Infections; Humans; Hydroxyurea; Lymphocyte Trans | 2004 |
Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoprolifera | 2007 |